{"entity":{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","aka":[],"tldr":"Pulmonologist appointed Superintendent of National Taiwan University Hospital in August 2025, leading Taiwan's flagship academic medical centre.","summary":"Chong-Jen Yu (余忠仁) has served as Superintendent of National Taiwan University Hospital since August 2025, the 17th superintendent in the hospital's National Taiwan University era. A professor of internal medicine and specialist in pulmonary and critical care medicine, he previously led NTUH's Hsin-Chu branch. As Superintendent he oversees the hospital's clinical services, including its cancer centre.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+CJ%5BAuthor%5D+National+Taiwan+University+Hospital"}],"tags":["leadership","pulmonology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ntuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm","pnas","lancet"],"dependsOn":[],"notes":[],"role":"Superintendent","institutionId":"ntuh","specialisms":["Pulmonology","Critical care medicine","Hospital leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+CJ%5BAuthor%5D+National+Taiwan+University+Hospital"}],"papers":[{"title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027071","doi":"10.1056/NEJMoa2027071","note":"Europe PMC author record matched by affiliation"},{"title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","journal":"Proceedings of the National Academy of Sciences","year":2007,"url":"https://doi.org/10.1073/pnas.0710370104","doi":"10.1073/pnas.0710370104","note":"Europe PMC author record matched by affiliation"},{"title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","journal":"Lancet","year":2017,"url":"https://doi.org/10.1016/S0140-6736(17)30123-X","doi":"10.1016/S0140-6736(17)30123-X","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0001-5664-9392"},"route":"/people/chong-jen-yu/","neighbours":{"institution":[{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"},{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/"},{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}],"trial":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/"}],"paper":[{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/"}]}}